| All Releases |
|---|
 |
Progenics Announces Initiation of RELISTOR Clinical Trials in Japan by Ono Pharmaceutical
Jun 8, 2009
|
16.6 KB
|
| |
TARRYTOWN, N.Y., Jun 08, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its
collaborator, Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528)
has begun clinical testing in Japan of RELISTOR(R)
(methylnaltrexone bromide) subcutaneous injection, the first-in-class
med...
|
|
|
Progenics Provides Update on Hepatitis C Program
Jun 8, 2009
|
13.1 KB
|
| |
TARRYTOWN, N.Y., Jun 08, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
discontinuation of development for PRO 206, a pre-clinical compound for
the treatment of hepatitis C virus (HCV) infection. The decision was
made as part of a portfolio review, and is in line with the Company's...
|
|
|
Progenics Announces First Quarter Financial Results
May 11, 2009
|
21.3 KB
|
| |
TARRYTOWN, N.Y., May 11, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the quarter ended March 31, 2009.
First Quarter Financial ResultsNet loss was $1.8 million or $0.06, basic and diluted, per share,
compared to $15.5 million or $0.52, basic and diluted, per s...
|
|
|
Phase 3 Clinical Study of RELISTOR Presented at American Pain Society Meeting Showed Positive Activity for the Treatment of Opioid-Induced Constipation in Chronic,Non-Cancer Pain Patients
May 7, 2009
|
22.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., May 07, 2009 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced results from the
one-month, double-blind portion of a phase 3 trial of RELISTOR(R)
(methylnaltrexone bromide) subcutaneous injection t...
|
|
|
Progenics Pharmaceuticals Reports Fourth Quarter and Year-End Results and Corporate Update
Mar 13, 2009
|
23.6 KB
|
| |
TARRYTOWN, N.Y., Mar 13, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its
results of operations for the fourth quarter and year ended December 31,
2008.
Revenues for the fourth quarter totaled $6.8 million, compared to $15.5
million for the same period of 2007. For the year ended De...
|
|
|
Progenics Selects Subcutaneous Form of PRO 140, A Novel HIV Antibody Therapy, For Further Development
Feb 10, 2009
|
75.3 KB
|
| |
Montreal, Quebec and Tarrytown, NY - February 10, 2009 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it has selected for further development the subcutaneous form of PRO 140 for the treatment of HIV infection. The decision follows positive results from a recently completed phase 2 clinical trial as well as feedbac...
|
|
|
Progenics Appoints Peter J. Crowley as Independent Board Member
Feb 4, 2009
|
13.2 KB
|
| |
TARRYTOWN, N.Y., Feb 04, 2009 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the
appointment of Peter J. Crowley to its Board of Directors as an
independent director. A senior healthcare investment banker with over 20
years' experience in the industry, Mr. Crowley will also serve on the
...
|
|
|
Announcement by Progenics Pharmaceuticals under Nasdaq Marketplace Rules
Dec 11, 2008
|
12.5 KB
|
| |
TARRYTOWN, N.Y., Dec 11, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it
has received a Nasdaq Staff Deficiency Letter indicating that it fails
to comply with Nasdaq's audit committee requirements. As a result of Mr.
Paul F. Jacobson's previously-announced resignation from the C...
|
|
|
Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain
Nov 26, 2008
|
19.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that a phase 3
clinical study investigating RELISTOR(R) (methylnaltrexone
bromide) subcutaneous injection to treat opioid-induced cons...
|
|
|
Progenics Announces Wyeth Has Received Relistor Approval in Australia
Nov 17, 2008
|
14.3 KB
|
| |
Tarrytown, NY, November 17, 2008 -Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced the Therapeutic Goods Administration (TGA) division of the Australian Government has approved the registration of RELISTOR® (methylnaltrexone bromide 12mg/0.6ml solution for injection) for the treatment of opioid-induced constipation (OIC...
|
|
|
Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates
Nov 10, 2008
|
20.1 KB
|
| |
TARRYTOWN, N.Y., Nov 10, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the third quarter and nine months ended September 30, 2008.
Revenues for the third quarter totaled $17.5 million, compared to $17.0 million for the same period of 2007. For the nine months ended September...
|
|
|
Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
Nov 4, 2008
|
14.7 KB
|
| |
SAN FRANCISCO & TARRYTOWN, N.Y., Nov 04, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection. Pre-clinical results supporting the development of PRO 206 wer...
|
|
|
Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms 0f Novel HIV Therapy PRO 140
Oct 26, 2008
|
227.1 KB
|
| |
Washington, DC and Tarrytown, NY - October 26, 2008 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced positive interim results from two separate phase 2 clinical trials of PRO 140 for the treatment of HIV infection. Both intravenous and subcutaneous forms of PRO 140, a novel viral-entry inhibitor, exhibited potent and prolo...
|
|
|
Progenics Pharmaceuticals and Ono Pharmaceutical Announce Agreement to Develop and Commercialize RELISTOR in Japan
Oct 16, 2008
|
16.2 KB
|
| |
TARRYTOWN, N.Y., Oct 16, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528) today announced an exclusive license agreement under which Ono has acquired the rights to RELISTOR(R) (methylnaltrexone bromide) in Japan, where it plans to develop and commercialize the U.S....
|
|
|
Progenics Announces Progress and Presentations in HIV Therapy Program
Oct 2, 2008
|
18.0 KB
|
| |
TARRYTOWN, N.Y., Oct 02, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the completion of enrollment in two, phase 2 clinical studies of PRO 140, an investigational drug that is being developed for treatment of human immunodeficiency virus (HIV) infection. The phase 2 studies are separately evaluating intrave...
|
|
|
Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer
Sep 8, 2008
|
18.7 KB
|
| |
TARRYTOWN, N.Y., Sep 08, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of a phase 1 dose-escalation clinical study of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). PSMA ADC is an investigational therapy that combines a prostate-cancer antibody with a cancer drug....
|
|
|
Progenics Pharmaceuticals Reports Second Quarter 2008 Results
Aug 8, 2008
|
21.7 KB
|
| |
TARRYTOWN, N.Y., Aug 08, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the second quarter and first half of 2008.
Revenues for the second quarter ended June 30, 2008 totaled $28.6 million compared to $25.5 million for the same quarter in 2007. For the first half of 2008, Pro...
|
|
|
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Jul 3, 2008
|
18.4 KB
|
| |
COLLEGEVILLE, Pa., & TARRYTOWN, N.Y., Jul 03, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received marketing approval for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the European Commission. RELISTO...
|
|
|
New England Journal Of Medicine Publishes Results From A Relistor Phase 3 Clinical Study
May 28, 2008
|
20.0 KB
|
| |
Collegeville, Pa., and Tarrytown, N.Y., May 28, 2008 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the publication of results from a pivotal phase 3 trial of RELISTORTM (methylnaltrexone bromide) subcutaneous injection in the May 29, 2008 issue of the New En...
|
|
|
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
May 22, 2008
|
20.5 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., May 22, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR(TM) (methylnaltrexone bromide).
...
|
|
|
